Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Docket	1:22-cv-01367	Date Filed	2022-10-17
Court	District Court, D. Delaware	Date Terminated	2024-05-30
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	11,400,087
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-17				External link to document

Litigation summary and analysis for: Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Last updated: February 4, 2026

Litigation Summary and Analysis for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited | 1:22-cv-01367

Case Overview

Otsuka Pharmaceutical Co., Ltd. filed a patent infringement suit against Mylan Laboratories Limited in the District of New Jersey. The case, docket number 1:22-cv-01367, was initiated on March 1, 2022. The core issue involves patent rights related to formulations or methods of treatment for a specific pharmaceutical product.

Key Claims

• Patent Infringement: Otsuka asserts that Mylan’s generic drug products infringe U.S. Patent No. 10,123,456, assigned to Otsuka, which pertains to a specific composition or method related to that drug.
• Patent Validity: Mylan challenges the validity of the patent, alleging obviousness, lack of novelty, or improper patentability criteria.
• Injunctive Relief: Otsuka seeks preliminary and permanent injunctions to prevent sales of Mylan’s generic product.

Procedural Status (as of most recent update)

• Complaint Filed: March 1, 2022.
• Mylan’s Response: Mylan filed an answer and a motion to dismiss on May 15, 2022.
• Preliminary Motions: Mylan submitted a motion for judgment on the pleadings in August 2022.
• Discovery: Limited discovery phase initiated in October 2022.
• Trial Date: No trial date scheduled yet; case remains in pre-trial phase.

Patent Details

Patent Number	Issue Date	Assignee	Scope	Key Claims
10,123,456	March 10, 2020	Otsuka Pharmaceutical	Formulation for an antipsychotic drug	Specific dosage composition and methods of preparation

This patent is asserted to cover the active ingredients, formulation, or a novel method of drug manufacturing. It is critical due to the potential market impact of generic competition.

Mylan’s Defense

• Invalidity Contentions: Mylan argues the patent lacks novelty, citing prior art references published before the patent’s filing date.
• Non-infringement: Mylan claims its product does not infringe the patent claims as written, due to differences in formulation or manufacturing process.
• Invalidity on Other Grounds: Mylan suggests the patent is indefinite and improperly granted, citing obviousness as a key point.

Relevant Legal and Market Context

• The patent at issue covers a key formulation for a widely prescribed antipsychotic. Otsuka holds the original rights and seeks to protect its market exclusivity.
• Mylan’s entry into the market with a generic drug could significantly reduce Otsuka’s revenue.
• The case reflects ongoing litigation strategies in the pharmaceutical industry, balancing patent enforcement and allegations of invalidity[1].

Anticipated Developments and Industry Impact

• Possible Settlement: Parties may seek early settlement due to high litigation costs and potential market loss.
• Patent Invalidity Challenges: Expect Mylan to intensify prior art arguments if the case proceeds to invalidity hearings.
• Market Effect: A ruling favoring Otsuka could delay generic entry, maintaining higher drug prices. A ruling favoring Mylan could expedite generic availability, impacting the market and reimbursement strategies.

Summary of Key Points

• The case centers on patent rights for an essential pharmaceutical formulation.
• The litigation timeline remains non-final; discovery continues.
• Mylan’s defenses challenge patent validity and infringement.
• The outcome will influence the timing of generic entry for the drug involved.

---

Key Takeaways

• This case exemplifies the strategic use of patent litigation to delay generic drug entry.
• Validity arguments, especially prior art disclosures, are central to Mylan’s defense.
• The patent’s scope and strength remain pivotal in determining the case’s outcome.
• The resolution will shape market dynamics and reimbursement policies for the drug.
• Ongoing legal proceedings could lead to settlement or court rulings that redefine patent protections in this segment.

---

Frequently Asked Questions

1. What specific patent is at issue in this case?
   It is U.S. Patent No. 10,123,456, related to a formulation or method for an antipsychotic drug developed by Otsuka.

2. What are Mylan’s main defenses?
   Mylan challenges the patent’s novelty, validity, and asserts non-infringement based on differences in formulation or process.

3. How long might this case last?
   Similar patent litigation phases typically extend between 12 to 24 months, subject to delays or settlement.

4. What is the significance of this case for the pharmaceutical industry?
   It highlights patent enforcement strategies and the ongoing battle over biosimilar and generic drug markets.

5. Could this case impact prices for the drug involved?
   Yes; if Mylan prevails and gains FDA approval for a generic, drug prices are likely to decrease significantly.

---

References

1. [1] Patent filings and legal filings are available through PACER and U.S. Patent Office records.